Conclusion
ONCOLOGY
Our study results indicated that IC-CRT therapy could be a suitable substitute for LC-CRT therapy due to the absence of any significant difference in the rates of pathological response and sphincter-sparing surgery, as well as offering the advantage of less risk of acute any hematological and skin side effects as a result of radiation. A Phase III randomized non-inferiority study would provide valuable additional information.The preliminary findings of this study were presented in a poster session at the 59th Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), which was held on September 24, 2017—September 27, 2017 in San Diego, United States and the abstract was published in International Journal of Oncology Biology Physics, Volume 49, Issue 2 Supplement S1–S272, e1–e759, October 2017. Abstract No. 2384.